Ranitidine 300 mg is used to treat and prevent a number of stomach and esophagus conditions caused by excess stomach acid [1]. These include:
* Ulcers: This involves sores in the lining of the stomach or the first part of the small intestine [1].
* Gastroesophageal Reflux Disease (GERD): This condition causes heartburn and regurgitation of food or sour liquid [1].
* Zollinger-Ellison Syndrome: This rare disorder causes the stomach to produce too much acid [1].
How does Ranitidine 300 mg work?
Ranitidine is a histamine H2-receptor antagonist. It works by reducing the amount of acid produced by the stomach [1].
What happened to Ranitidine products?
Many ranitidine products were voluntarily recalled and have been discontinued from the U.S. market due to the presence of N-Nitrosodimethylamine (NDMA), a probable human carcinogen [2]. This recall began in 2019 and has led to a significant reduction in the availability of ranitidine [2][3].
What are the alternatives to Ranitidine?
Due to the discontinuation of ranitidine, alternative medications are now commonly used to manage conditions previously treated with ranitidine. These include other H2-receptor antagonists and proton pump inhibitors (PPIs) [4].
* Other H2-receptor antagonists: Famotidine (Pepcid), cimetidine (Tagamet), and nizatidine (Axid) are examples of H2 blockers that are still available [4].
* Proton Pump Inhibitors (PPIs): Medications like omeprazole (Prilosec), lansoprazole (Prevacid), esomeprazole (Nexium), and pantoprazole (Protonix) are also widely prescribed for acid-related conditions [4]. These drugs are generally more potent than H2 blockers in reducing stomach acid [5].
What are the risks associated with Ranitidine?
The primary concern that led to the withdrawal of ranitidine from the market was the detection of NDMA [2]. NDMA is classified as a probable human carcinogen, meaning it may cause cancer [6]. Studies indicated that NDMA could form in ranitidine products over time and with exposure to certain temperature conditions [3].
What is the history of Ranitidine recalls?
The U.S. Food and Drug Administration (FDA) requested the withdrawal of all ranitidine products from the U.S. market in April 2020, following earlier voluntary recalls initiated by manufacturers in 2019 [2][3]. This action was taken after ongoing testing confirmed unacceptable levels of NDMA in various ranitidine products [2].
Sources:
[1] https://www.nlm.nih.gov/medlineplus/druginfo/meds/a601047.html
[2] https://www.fda.gov/drugs/drug-recalls/furan-and-benzoic-acid-methyl-ester-and-ranitidine-products-recalls-and-market-withdrawals
[3] https://www.drugpatentwatch.com/drug/ranitidine
[4] https://www.mayoclinic.org/drugs-supplements/ranitidine-oral-route-parenteral-route/proper-use/drg-20068155
[5] https://www.health.harvard.edu/diseases-and-conditions/heartburn-and-acid-reflux
[6] https://www.epa.gov/sites/default/files/2015-09/documents/ndma-fact-sheet-2008.pdf